SCHEMBL30768600

SCHEMBL30768600

O=C1CCN(c2ccc(N3CC[C@@]4(CCNC4)C3)cc2)C(=O)N1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 4/20 0.51
CRBN Q96SW2 4/20 0.51
CYP2D6 P10635 9/20 0.51
ALDH1A1 P00352 9/20 0.51
CYP3A4 P08684 8/20 0.51
USP2 O75604 7/20 0.51
CYP1A2 P05177 6/20 0.51
HSD17B10 Q99714 6/20 0.50
CYP2C19 P33261 5/20 0.50
TP53 P04637 4/20 0.50
MAPK1 P28482 4/20 0.50
HPGD P15428 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
TSHR P16473 6/20 0.41
KHK P50053 1/20 0.41
CYP2C9 P11712 2/20 0.40
ESRRG P62508 1/20 0.40
USP28 Q96RU2 1/20 0.39
USP25 Q9UHP3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30769340 1.00 DDB1 (0.51) DDB1CRBNCYP2D6ALDH1A1CYP3A4
SCHEMBL30723747 0.92 CRBN (0.54) DDB1CRBNCYP2D6ALDH1A1CYP3A4
SCHEMBL31306915 0.87 CRBN (0.56) DDB1CRBNCYP2D6ALDH1A1CYP3A4
SCHEMBL23267981 0.82 CRBN (0.54) DDB1CRBNALDH1A1CYP3A4USP2
SCHEMBL1426558 0.78 CYP2D6 (0.61) CYP2D6ALDH1A1CYP3A4USP2CYP1A2
SCHEMBL30769297 0.77 ALDH1A1 (0.49) DDB1CRBNCYP2D6ALDH1A1CYP3A4
SCHEMBL20455740 0.76 CYP2D6 (0.60) CYP2D6ALDH1A1CYP3A4USP2CYP1A2
SCHEMBL20842185 0.76 CYP2D6 (0.60) CYP2D6ALDH1A1CYP3A4USP2CYP1A2
SCHEMBL30769043 0.76 DDB1 (0.48) DDB1CRBNCYP2D6ALDH1A1CYP3A4
SCHEMBL1426810 0.76 CYP2D6 (0.82) CYP2D6ALDH1A1CYP3A4USP2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388565-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2025-12-25 US disclosed
EP-4543871-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF Relay Therapeutics, Inc. (US) 2025-04-30 EP disclosed
WO-2024006781-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF RELAY THERAPEUTICS, INC. (US) 2024-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388565-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF ESRRA, ESRRB, ESR2 DDB1 2204/4885CRBN 488/4885CYP2D6 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.